200 related articles for article (PubMed ID: 30832603)
21. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
Wang Y; Fan S; Zhong W; Zhou X; Li S
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
[TBL] [Abstract][Full Text] [Related]
22. Establishing in vitro-in vivo correlation for antibody drug conjugate efficacy: a PK/PD modeling approach.
Shah DK; Loganzo F; Haddish-Berhane N; Musto S; Wald HS; Barletta F; Lucas J; Clark T; Hansel S; Betts A
J Pharmacokinet Pharmacodyn; 2018 Apr; 45(2):339-349. PubMed ID: 29423862
[TBL] [Abstract][Full Text] [Related]
23. Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
Kågedal M; Gibiansky L; Xu J; Wang X; Samineni D; Chen SC; Lu D; Agarwal P; Wang B; Saad O; Koppada N; Fine BM; Jin JY; Girish S; Li C
J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):537-548. PubMed ID: 28918591
[TBL] [Abstract][Full Text] [Related]
24. Cellular-Resolution Imaging of Bystander Payload Tissue Penetration from Antibody-Drug Conjugates.
Khera E; Dong S; Huang H; de Bever L; van Delft FL; Thurber GM
Mol Cancer Ther; 2022 Feb; 21(2):310-321. PubMed ID: 34911819
[TBL] [Abstract][Full Text] [Related]
25. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads.
Masters JC; Nickens DJ; Xuan D; Shazer RL; Amantea M
Invest New Drugs; 2018 Feb; 36(1):121-135. PubMed ID: 29027591
[TBL] [Abstract][Full Text] [Related]
26. A Brief Introduction to Antibody-Drug Conjugates for Toxicologic Pathologists.
Mecklenburg L
Toxicol Pathol; 2018 Oct; 46(7):746-752. PubMed ID: 30295169
[TBL] [Abstract][Full Text] [Related]
27. Antibody-Drug Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class.
Lerchen HG; Wittrock S; Stelte-Ludwig B; Sommer A; Berndt S; Griebenow N; Rebstock AS; Johannes S; Cancho-Grande Y; Mahlert C; Greven S; Terjung C
Angew Chem Int Ed Engl; 2018 Nov; 57(46):15243-15247. PubMed ID: 30180286
[TBL] [Abstract][Full Text] [Related]
28. Mechanistic Modeling of Intra-Tumor Spatial Distribution of Antibody-Drug Conjugates: Insights into Dosing Strategies in Oncology.
Weddell J; Chiney MS; Bhatnagar S; Gibbs JP; Shebley M
Clin Transl Sci; 2021 Jan; 14(1):395-404. PubMed ID: 33073529
[TBL] [Abstract][Full Text] [Related]
29. Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety.
Wang Y; Liu L; Fan S; Xiao D; Xie F; Li W; Zhong W; Zhou X
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32245171
[TBL] [Abstract][Full Text] [Related]
30. Hydrophilic Auristatin Glycoside Payload Enables Improved Antibody-Drug Conjugate Efficacy and Biocompatibility.
Satomaa T; Pynnönen H; Vilkman A; Kotiranta T; Pitkänen V; Heiskanen A; Herpers B; Price LS; Helin J; Saarinen J
Antibodies (Basel); 2018 Mar; 7(2):. PubMed ID: 31544867
[TBL] [Abstract][Full Text] [Related]
31. [Design of next generation antibody drug conjugates].
Zhu GD; Fu YX
Yao Xue Xue Bao; 2013 Jul; 48(7):1053-70. PubMed ID: 24133971
[TBL] [Abstract][Full Text] [Related]
32. Development of a Novel DNA Mono-alkylator Platform for Antibody-Drug Conjugates.
Thomas JD; Yurkovetskiy AV; Yin M; Bodyak ND; Tang S; Protopopova M; Kelleher E; Jones B; Yang L; Custar D; Catcott KC; Demady DR; Collins SD; Xu L; Bu C; Qin L; Ter-Ovanesyan E; Damelin M; Toader D; Lowinger TB
Mol Cancer Ther; 2024 Apr; 23(4):541-551. PubMed ID: 38354416
[TBL] [Abstract][Full Text] [Related]
33. Determination of ADC Cytotoxicity in Immortalized Human Cell Lines.
Wu S; Shah DK
Methods Mol Biol; 2020; 2078():329-340. PubMed ID: 31643068
[TBL] [Abstract][Full Text] [Related]
34. NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effects.
Nicolaides NC; Kline JB; Grasso L
PLoS One; 2023; 18(5):e0285161. PubMed ID: 37195923
[TBL] [Abstract][Full Text] [Related]
35. A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates.
Ait-Oudhia S; Zhang W; Mager DE
AAPS J; 2017 Sep; 19(5):1436-1448. PubMed ID: 28646408
[TBL] [Abstract][Full Text] [Related]
36. Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of Lymphoma.
Jagadeesh D; Smith MR
Curr Treat Options Oncol; 2016 Oct; 17(10):55. PubMed ID: 27544507
[TBL] [Abstract][Full Text] [Related]
37. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
38. Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.
Rossi C; Chrétien ML; Casasnovas RO
Target Oncol; 2018 Jun; 13(3):287-308. PubMed ID: 29556925
[TBL] [Abstract][Full Text] [Related]
39. Impact of Payload Hydrophobicity on the Stability of Antibody-Drug Conjugates.
Buecheler JW; Winzer M; Tonillo J; Weber C; Gieseler H
Mol Pharm; 2018 Jul; 15(7):2656-2664. PubMed ID: 29809017
[TBL] [Abstract][Full Text] [Related]
40. Catabolism of antibody drug conjugates and characterization methods.
Shadid M; Bowlin S; Bolleddula J
Bioorg Med Chem; 2017 Jun; 25(12):2933-2945. PubMed ID: 28438386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]